GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

GETI.B

213

+0.42%↑

BIOAB

314.2

-1.69%↓

EKTA.B

57.05

+1.42%↑

VITR

137.9

+3.84%↑

AMBEA

141.3

-0.14%↓

Home・Aktien・Camurus AB

Camurus AB

Geschlossen

601.5 -1.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

594

Max

608.5

Schlüsselkennzahlen
By Trading Economics
Einkommen	-99M 193M
Verkäufe	-108M 567M
KGV Branchendurchschnitt	46.937 76.798
EPS	3.19
Gewinnspanne	33.972
Angestellte	280
EBITDA	-62M 253M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	432M 37B
Vorheriger Eröffnungskurs	602.65
Vorheriger Schlusskurs	601.5

Camurus AB Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Dez. 2025, 17:29 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. Dez. 2025, 16:47 UTC

Wichtige Markttreiber

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. Dez. 2025, 16:10 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

21. Dez. 2025, 23:51 UTC

Market Talk

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

21. Dez. 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Dez. 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

21. Dez. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

19. Dez. 2025, 22:33 UTC

Ergebnisse

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. Dez. 2025, 22:19 UTC

Ergebnisse

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. Dez. 2025, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 21:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 21:38 UTC

Ergebnisse

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. Dez. 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. Dez. 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. Dez. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. Dez. 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. Dez. 2025, 18:00 UTC

Market Talk

Ergebnisse

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. Dez. 2025, 17:41 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 17:24 UTC

Market Talk

Ergebnisse

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. Dez. 2025, 16:29 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. Dez. 2025, 16:20 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. Dez. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. Dez. 2025, 16:18 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. Dez. 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Dez. 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. Dez. 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 16:04 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Peer-Vergleich

Kursveränderung

Camurus AB Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.